Bibliography
- GABIZON A: Selective tumor localization and improved therapeutic index of anthracylines encapsulated in long-circulating liposomes. Cancer Res. (1992) 52(4):891–896.
- FLEMING AB, SALTZMAN WM: Pharmacokinetics of the carmustine implant. Clin. Pharmacokinet. (2002) 41(6):403–419.
- LI LC, DENG J, STEPHENS D: Polyanhydride implant for antibiotic delivery-from the bench to the clinic. Adv. Drug Del. Rev (2002) 54:963–986.
- •A recent review of the development of a polyanhydride implant.
- GUPTE A, CIFTCI K: Formulation and characterization of paclitaxel, 5-FU and paclitaxel +5-FU microspheres. bit. Pharm. (2004) 276:93–106.
- LAGARCE F, RENAUD P, FAISANT N et al.: Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model. Eur. I Pharm. Biopharm. (2005) 59:449–459.
- NARAHARISETTI PK, LEW MD, FU Y- LEE D- WANG C-H: Gentamicin-loaded discs and microspheres and their modifications: characterization and in vitro release. I Control. Release (2005) 102:345–359.
- CUI F, CUN D, TAO A et al: Preparation and characterization of melittin-loaded poly(D,t-lactic acid) or poly(D,t-lactic-co-glycolic acid) microspheres made by the double emulsion method. Control. Release (2005) (In press).
- KOSTANSKI JW, DANI BA, REYNOLDS GA, BOWERS CY, DELUCA PP: Evaluation of orntide microspheres in a rat animal model and correlation to in vitro release profiles. AAPS Pharm. Sci. Tech. (2000) 1(4):E27.
- BLANCO-PRIETO MJ, CAMPANERO MA, BESSEGHIR K, HEIMGATNER F, GANDER B: Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres. J. Control. Release (2004) 96:437–448.
- JIANG W, GUPTA RK, DESHPANDE MC, SCHWENDEMAN SP: Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Del. Rev (2005) 57:391–410.
- SINHA VR, TREHAN A: Biodegradable microspheres for protein delivery. J. Control. Release (2003) 90:261–280.
- •A recent overview of protein delivery by biodegradable microspheres.
- RADULESCU D, WADE N, WAWRO D: Uniform paclitaxel-loaded biodegradable micropsheres manufactured by ink-jet technology. Proceedings of the Whiter Symposium and 11th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, USA (2003).
- CLELAND JL, JOHNSON OL, PUTNEY S, JONES AJ: Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development. Adv. Drug Del. Rev (1997) 28:71–84.
- •The first review of the development of PLG microspheres of a recombinant protein.
- YEO Y, PARK K: A new microencapsulation method using an ultrasonic atomizer based on interfacial solvent exchange. J. Control. Release (2004) 100(3):379–388.
- •The first report on the interfacial solvent-exchange method for fabrication of polymeric microspheres.
- ELVASSORE A, BERTUCCO A, CALICETI P: Production of insulin-loaded poly(ethylene glycol)/poly(lactide) (PEG/ PLA) nanoparticles by gas antisolvent techniques. J. Pharm. Sci. (2001) 90(10):1628–1636.
- ELVASSORE N, BERTUCCO A, CALICETI P: Production of protein-loaded polymeric microcapsules by compressed CO2 in a mixed solvent. Lid. Eng. Chem. Res. (2001) 40:795–800.
- WHITAKER MJ, HAO J, DAVIES OR et al.: The production of protein-loaded microparticles by supercritical fluid enhanced mixing and spraying. I Control. Release (2005) 101(1-3):85–92.
- •A recent report on the fabrication of protein-loaded polymeric microspheres by supercritical fluid.
- HOWDLE SM, WATSON MS, WHITAKER MJ et al.: Supercritical fluid mixing: preparation of thermally sensitive polymer composites containing bioactive materials. Chem. Comm. (2001) 1:109–110.
- KISSEL T, LI YX, VOLLAND C, GORICH S, KONEBERG R: Parenteral protein delivery systems using biodegradable polyesters of ABA block structure, containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethylene oxide) B blocks. J. Control. Release (1996) 39(2–3):315-326.
- RONNEBERGER B, KISSEL T, ANDERSON JM: Biocompatibility of ABA triblock copolymer microparticles consisting of poly(t-lactic-co-glycolic-acid) A-blocks attached to central poly(oxyethylene) B-blocks in rats after intramuscular injection. Eur. Pharma. Biopharm. (1997) 43(1):19–28.
- MORLOCK M, KISSEL T, LI YX, KOLL H, WINTER G: Erythropoietin loaded microspheres prepared from biodegradable LPLG-PEO-LPLG triblock copolymers: protein stabilization and in vitro release properties. ./. Control. Release (1998) 56(1-3):105–115.
- BREITENBACH A, LI YX, KISSEL T: Branched biodegradable polyesters for parenteral drug delivery systems. ./. Control. Release (2000) 64(1-3):167–178.
- LI Y, NOTHNAGEL J, KISSEL T: Biodegradable brush-like graft polymers from poly(0, t-lactide) or poly(0, Irlactide-co-glycolide) and charge-modified, hydrophilic deArans as backbone-synthesis, characterization and in vitro degradation properties. Polymer (1997) 38(25):6197–6206.
- BELETSI A, PANAGI Z, AVGOUSTAKIS K: Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int. J. Pharm. (2005) 298(1):233–241.
- SINHA VR, AGGARWAL A, TREHAN A: Biodegradable PEGylated microspheres and nanospheres. Am. J. Drug Deify. (2005) 2(3):157–171.
- •A recent review of pegylated microspheres and nanospheres.
- SINHA VR, BANSAL K, KAUSHIK R, KUMRIA R, TREHAN A: Poly-c - caprolactone microspheres and nanospheres: an overview. hit. Pharm. (2004) 278: 1–23.
- •A recent overview of polycaprolactone technology.
- SHENOY DB, D'SOUZA RJ, TIWARI SB, UDUPA N: Potential applications of polymeric microsphere suspension as subcutaneous depot for insulin. Drug Dev. Ind. Pharm. (2003) 29(5):555–563.
- MARTIN LG, COLLETT JH, ATTWOOD D: The release of 5-fluorouracil from microspheres for poly(c-caprolactone-co-ethylene oxide). Drug Dev.Pharm. (2000) 26(1)7–12.
- ZHOU S, DENG X, YANG H: Biodegrdable poly(c-caprolactone)-poly(ethylene glycol) block copolymers: characterization and their use as drug carriers for a controlled delivery system. Biomaterials (2003) 24:3563–3570.
- DONG C- GUO Y- QIU K- GU Z- FENG X-D: In vitro degradation and controlled release behavior of D, L-PLGA50 and PCL-b-D,L-PLGA50 copolymer microspheres. J. Control. Release (2005) 107:53–64.
- HARPER E, DANG W, LAPIDUS RG, ROBERT I, GARVER J: Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin. Cancer Res. (1999) 5:4242–4248.
- XU X, YU H, GAO S et al.: Polyphosphoester microspheres for sustained release of biologically active nerve growth factor. Biomaterials (2002) 23(17):3765–3772.
- WANG J, MAO H- LEONG KW: A novel biodegradable gene carrier based on polyphosphoester. J. Am. Chem. Soc. (2001) 123:9480–9481.
- LI KW, DANG W, TYLER BM et al.: Polilactofate microspheres for paclitaxel delivery to central nervous system malignancies. Clin. Cancer Res. (2003) 9:3441–3447.
- KUMAR N, LANGER RS, DOMB AJ: Polyanhydrides: an overview. Adv. Drug Del. Rev (2002) 54:889–910.
- JAIN JP, MODI S, DOMB AJ, KUMAR N: Role of polyanhydrides as localized drug carrier. J. Control. Release (2005) 103:541–563.
- •A recent overview of polyanhydrides for localised drug delivery.
- HELLER J, BARR J: Biochronomer technology. Expert Opia Drug Delivery (2005) 2(1):169–183.
- •A recent review of polyorthoesters for parenteral drug delivery.
- NG SY, SHEN HR, LOPEZ E et al: Development of a poly(ortho ester) prototype with a latent acid in the polymer backbone for 5-fluorouracil delivery. J. Control. Release (2000) 65:367–374.
- ROTHEN-WEINHOLD A, SCHWACH-ABDELLAOUI K, BARR J et al: Release of BSA from poly(ortho ester) extruded thin strands. J. Control. Release (2001) 71:31–37.
- DENG J- LI L, TIAN Y et al.: Li vitro characterization of polyorthoester microparticles containing bupivacaine. Pharm. Develop. Technol (2003) 8(1):31–38.
- BAI X- YANG Y- CHUNG T- NG S, HELLER J: Effect of polymer compositions on the fabrication of poly(ortho-ester) microspheres for controlled release of protein. J. Appli. Polymer Sci (2001) 80(10):1630–1642.
- FOURNIER E, PASSIRANI C, COLIN N et al.: Development of novel 5-FU-loaded poly(methylidene malonate 2.1.2)-based microspheres for the treatment of brain cancers. Eur. Pharm. Biopharm. (2004) 57(2):189–197.
- YANG Y- WAN J- CHUNG T-S et al.: POE-PEG-POE triblock copolymeric microspheres containing protein: I. Preparation and characterization. J. Control. Release (2001) 75(1-2):115–128.
- DESCHAMPS AA, GRIJPMA DW, GEIJEN J: Poly(ethylene oxide)/poly(butylenes teraphthalate) segmented block copolymers: the effect of copolymer composition on physical properties and degradation behavior. Polymer (2001) 42: 9335–9345.
- DESCHAMPS AA, APELDOORN AA, HAYEN H et al: LI vivo and in vitro degradation of poly(ether ester) block copolymers based on poly(ethylene glycol) and poly(butylene terephthalate). Biomaterials (2004) 25(2):247–258.
- JANSEN JA, RUIJTER JE, JANSSEN PT, PAQUAY YG: Histological evaluation of a biodegradable polyactive/hydroxyapatite membrane. Biomaterials (1995) 16(11):819–827.
- BEZEMER JM, RADERSMA R, GRIJPMA DW et al: Microspheres for protein delivery prepared from amphiphilic multiblock copolymers 2. Modulation of release rate. J. Control. Release (2000) 67:249–260.
- FRANSSEN O, VENDERVENNET L, RODERS P, HENNINK WE: Degradable dextran hydrogels: controlled release of a model protein from cylinders and microspheres. J. Control. Release (1999) 60:211–221.
- STENEKES RJH, FRANSSENO 0, BOMMEL WM, CROMMELIN DJ, HENNINK WE: The use of aqueous PEG/ dextran phase separation for the preparation of dextran microspheres. Int. J. Pharm. (1999) 183:29–32.
- CHUNG JT, VLUGT-WENSINK HENNINK WE, ZHANG Z: Effect of polymerization conditions on the network properties of dex-HEMA microspheres and macro-hydrogels. Lk. Pharm. (2005) 288:51–61.
- STENEKES RJ, HENNINK WE: Equilibrium water content of microspheres based on cross-linked dextran. Int. J. Pharm. (1999) 189:131–135.
- CADEE JA, DEGROOT CJ, JISKOOT W,OTTER WD, HENNINK WE: Release of recombinant human interleukin-2 from dextran-based hydrogels. J. Control. Release (2002) 778:1–13.
- KOTEN JW, LUYN MJ, CADEE JA et al: IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. Cytokine (2003) 24:57–66.
- GROOT CJ, VAN LUYN MJ, VAN DIJK-WOLTHUIS WN et al: In vitro biocompatibility of biodegradable dextran-based hydrogels tested with human fibroblasts. Biomaterials (2001) 22(10:1197–1203.
- CONSTANCIS A, MEYRUEIX R, BRYSON N et al: Macromolecular colloids of diblock poly(amino acids) that bind insulin. J. Colloid Interface Li. (1999) 217(2):357–368.
- KOCH M, STEIDLE C, BROSMAN S et al.: An open-label study of abarelix in men with sympotomatic prostate cancer at risk of treatment with LHRH agonist. Urology (2003) 62 (5):877–882.
- KNIGHTH CG: Liposomes: From PhysicalStructure To Therapeutic Application. Elsevier/North Holland Biomedical Press, New York, NY, USA (1981):381–390.
- MAEDA H, SAWA T, KONNO T: Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release (2001) 74:47–61.
- STROM G, OUSSOREN C, PEETERS P, BARNHOLZ Y: Tolerabillity of liposomes in vivo. In: Liposome Technology. G Gregoriadis (Ed.), CRC Press, Boca Raton, FL, USA (1993):345–383.
- WOODLE M: Controlling liposome blood clearances by surface-grafted polymers. Adv. Drug Del. Rev (1998) 32:139–152.
- CEH B, WINTERHALTER M, FREDERIK PM, VALLNER JJ, LASCI DD: Stealth liposomes: from theory to product. Adv. Drug Del. Rev (1997) 24:165–177.
- •An overview of stealth liposomes providing excellent background information.
- IMMORDINAO ML, BRUSA P, ARPICCO S et al: Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control. Release (2003) 91:417–429.
- SETHI V, ONYUKSEL H, RUBINSTEIN I: Liposomal vasoactive interstinal peptide. Meth. Enzym. (2005) 391:377–395.
- HAGEN TL: Lipsomal cytokines in the treatment of infectious diseases and cancer. Meth. Enzym. (2005) 391:125–145.
- SLOOTEN ML, BOERMAN 0, ROMOREN K et al: Liposomes as sustained release system for human interferon-y: biopharmaceutical aspect. Bioch. Biophys. ACTA (2001) 1530:134–145.
- FELNEROVA D, VIRET JF, GLUCK R, MOSER C: Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotech. (2004) 15:518–529.
- •The first article providing a thorough discussion on the potential applications of virosomes.
- OKU N, NAMBA Y: Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents. Meth. Enzymol (2005) 391:145–162.
- ALLEN TM: Ligand-targeted therapeutics in anticancer therapy. Nat. Rev Cancer (2002) 2:750–764.
- FORSSEN E, WILLIS M: Ligand-targeted liposomes. Adv.Drug Del. Rev (1998) 29:249–271.
- ZHANG JA, ANYARAMBHATLA G, MA L et al.: Development and charaterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur. j Pharm. Biopharm. (2005) 59(1):177–187.
- ZHANG JA, XUAN T, PARMAR M et al.:Development and charaterization of a novel liposome-based formulation of SN-38. Int. J. Pharm. (2004) 270(1-2):93–107.
- WATERHOUSE DN, MADDEN TD, CULLIS PR et al: Preparation, characterization and biological analysis of liposomal formulation of vincristine. Meth. Enzym. (2005) 391:40–57.
- OUSSORE C, STORM G, CROMMELIN DJ, SENIOR JH: In: Liposomes for local sustained drug release (Chapter J Senior et al. (Eds), Interpharm/CRC, Press, Boca Raton, FL, USA (2000):
- MANTRIPRAGADA S: A lipid based depot (DepoFoam® technology) for sustained release drug delivery. Prog. Lipid Res. (2002) 41(5):392–406.
- •A good introductory article on the DepoFoam technology.
- YE Q, ASHERMAN J, STEVENSON M, BROWNSON E, KATRE NV: DepoFoam Tm technology: a vehicle for controlled delivery of protein and peptide drugs. J. Control. Release (2000) 64(1-3):155–166.
- WESTESE K, BUNJAS H, KOCH MH: Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control. Release (1997) 48:223–236.
- DELCURTO MD, CHICCO D, D'ANTONIO M et al: Lipid microparticles as sustained release system for a GnRH antagonist (Antide). I Control. Release (2003) 89(2):297–310.
- LI LC, ZHU L, SONG JF et al: Effect ofsolid state transition on the physical stability of suspensions containing bupivacaine lipid microparticles. Pharm. Dev. Tech (2005) 10:309–318.
- SCHOLER N, KRAUSE K, KAYSER 0 et al.: Atovaquone nanosuspensions slow excellent therapeutic effect in a new murin model of reactivated toxoplamosis. Atritimicrob. Agents. Chemother. (2001) 45:1771–1779.
- REITHMEIER H, HERRMANN J, GOPFERICH A: Development and characterization of lipid microparticles as a drug carrier for somatostatin. Int. J. Pharm. (2001) 218(1-2):133–143.
- REITHMEIER H, HERRMANN J, GOPFERICH A: Lipid microparticles as a parenteral controlled release device for peptides. J. Control. Release (2001) 73(2-3):339–350.
- ENGWICHT A, GIRRESER U, MOLLER BW: Characterization of co-polymers of lactic and glycolic acid for supercritical fluid processing. Biomaterials (2000) 21(15):1587–1593.
- SANTOS IR, RICHARD J, PECH B, THIES C, BENOIT JP: Microencapsulation of protein particles within lipids using a novel supercritical fluid process. Int. J. Pharm. (2002) 242(1-2):69–78.
- TOONGSUWAN S, LI LC, ERICKSON BK, CHANG HC: Formulation and characterization of bupivacaine lipospheres. Int. Pharm. (2004) 280(1-2):57–65.
- PAPAHADJOPOULOS D, VAIL WJ, JACOBSON K, POST G: Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim. Biophys. Acta. (1975) 394:483–491.
- ZARIF L: Drug delivery by lipid cochleates.Meth. Enzym. (2005) 391:314–329.
- •A recent overview of cochleates.
- ZARIF L, MANNINO RJ: Cochleates. In: Cancer Gene Therapy: Past Achievement and Future Challenge. N Habib (Ed.), Kluwer Academic/Plenum, New York, NY, USA (2000):83–94.
- ZARIF L, PERLIN D: Amphotericin B nonocholeates: from formulation to oral efficacy. Drug Deily. Tech. (2002) 2(4)
- SEGARRA I, MOVSHIN DA, ZARIF L: Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system. I Pharm. Sci. (2002) 91(8):1827–1837.
- BRACHO G, LASTRE M, CAMPO JD et al: Proteoliposome derived cochleate as novel adjuvant. Vaccine (2005) (In press).
- GOULD-FOGERITE S, KHEIRI M, ZHANG F, MANNINO RJ: Cochleate delivery vehicles: applications in vaccine delivery. ,/. Liposome Res. (2001) 10:339–356.
- GOULD-FOGERITE S, MANNINO RJ: Cochleate delivery vehicles: applications to gene therapy. Drug Del. Tech. (2003) 3(2)
- PACKHAEUSER C, SCHNIEDERS J, OSTER CG, KISSEL T: in situ forming parenteral drug delivery systems: an overview. Eur. Pharm. Biopharm. (2004) 58:445–455.
- •A recent overview of in situ depot-forming systems for parenteral drug delivery.
- MARTINI A, LAURIA S: Sustained release injectable products. Am. Pharm. Rev (2003) 6(3):16–20.
- TIPTON AJ, DUNN RL: In situ gelling systems. In: Sustained-Release Injectable Products. JH Senior et al. (Eds), Interpharm Press, Boca Rota, FL, USA (2000):241–278.
- SARTOR O: Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology (2003) 61(2 Suppl. 1):25–31.
- OKUMU FW, DAO LN, FIELDER PJ et al: Sustained delivery of human growth hormone from a novel gel system: SABERTM. Biomaterials (2002) 23(22):4353–4358.
- ZENTNER GM, RATHI R, SHIH C et al: Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J. Control. Release (2001) 72:203–215.
- •A good introductory article on the applications of block copolymers for parenteral drug delivery.
- MASAKI T, RATHI R, ZENTNER G et al: Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney mt. (2004) 66(5):2061–2069.
- CHOI S, KIM SW: Controlled release of insulin from injectable biodegradable triblock copolymer depot in ZDF rats. Pharm. Res. (2003) 20:2008–2010.
- CHENITE A, CHAPUT C, WANG D et al.: Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials (2000) 21(20:2155–2161.
- BERRADA M, SERREQI A, DABBARH F et al.: A novel non-toxic camptothecin formulation for cancer chemotherapy. Biomaterials (2005) 26(14):2115–2120.
- YONG CS, CHOI JS, QUAN QZ et al: Effect of sodium chloride on the gelation temperature, gel strength and bioadhesive forces of poloxamer gels containing diclofenac sodium. Int. I Pharm. (2001) 226(1-2):195–205.
- WASAN KM, SUBRANMANIAN R, KWONG M et al: Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. I Pharmacol Pharm. Li. (2003) 6(2):189–197.
- QIU Q, STEFANOS S, MA J et al.: A hydrogel prepared by in situ cross-linking of a thiol-containing poly(ethylene glycol)-based copolymer: a new biomaterial for protein drug delivery. Biomaterials (2002) 24(1):11–18.
- OSTER CG, WITTMAR M, UNGER F et al.: Design of Amin-modified graft polyesters for effective gene delivery using DNA-loaded nanoparticles. Pharm. Res. (2004) 21(6):927–931.
- PACKHAUSER C, WITTMAR M, KISSEL T: Novel in situ forming implants for bioactive macromolecules based on positively charged nanoparticles: preparation of insulin-loaded nanoparticles, characterization of depots and investigation of insulin release. CRS Annual Meet-Mg. Miami, FL, USA (2005).
- HELLER J, BARR J, NG S, SHEN HR: Injectable semi-solid poly(ortho esters) for the controlled delivery of therapeutic agents: synthesis and applications. Drug Del. Technol. (2002) 2(1)
- DOMB AJ, ISRAEL ZH, ELMALAK 0: Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors. Pharm. Res. (1999) 16(5):762–765.
- ALLABABIDI S, SHAH JC: Efficacy and pharmacokinetics of site-specific cefazolin delivery using biodegradable implants in the prevention of post-operative wound infections. Pharm. Res. (1998) 15(2):325–333.
- CHILUKURI DM, SHAH JC: Local delivery of vancomycin for the prophylaxis of prosthetic device-related infections. Pharm. Res. (2005) 22(4):563–572.
- CROXATTO HB: Progestin implants. Steroids (2000) 65:681–685.
- COSTANTINI LC, KLEPPNER SR, MCDONOUGH J, AZAR MR, PATEL R: Implantable technology for long-term delivery of nalmefene for treatment of alcoholism. Int. J. Pharm. (2004) 283:35–44.
- WRIGHT JC, CHESTER AE, SKOWRONSKI RJ, LUCAS C: Long term controlled delivery of therapeutic agents via an implantable osmotically driven system: the DUROS implant. In: Modified-Release Drug Delivery Technology MJ Rathbone et al. (Eds), Marcel Dekker, New York, NY, USA (2003):657–669.
- WRIGHT JC, LEONARD ST, STEVENSON CL et al: An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J. Control. Release (2001) 75(1-2):1–10.
- WRIGHT JC, JOHNSON RM, YUM SL: DUROS osmotic pharmaceutical systems for parenteral and site directed therapy. Drug Del 7echnol. (2003) 3(1).
- •A recent review of the Duros technology.
- DEHNAD H, BERRY S, FEREIRA P et al.: Functionality of osmotically driven, implantable therapeutic systems (DUROS implant): effects of osmotic pressure and delivery of suspension formulations of peptides and proteins. Proc. Int. Symp. Control. Rel. Bioact. Mater (2000) 27:1016–1017.
- FOWLER JE, GOTTESMAN JE, REID CF, ANDRIOLE GL, SOLOWAY M: Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J. Urology (2000) 164:730–734.
- REYNOLDS L, RAUCK R, WEBSTER L et al.: Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. Path (2004) 110(1-2):182–188.
- CHERTIN B, SPITZ IM, LINDENBERG T et al.: An implant releasing the gonadotropin hormone-releasing hormonte agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J. Urology (2000) 163(3):838–844.
- GREENWALD RB: Effective drug delivery by pegylated drug conjugates. Adv. Drug Del. Rev (2003) 55:217–250.
- •A recent overview of pegylated drug conjugates for parenteral drug delivery of proteins.
- JAIN S, HRECZU-HIRST DH, MCCORMACK B et al.: Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim. Biophys. Acta (2003) 1622:42–49.
- CALICETI P, VERONESE FM: Pharmacokinetic and biodistribution properties of poly(ethylene glycol) -proteinconjugates. Adv. Drug Del. Rev (2003) 55:1261–1277.
- TSUNODA S, ISHIKAWA T, YAMAMOTO Y et al.: Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-a: a novel polymer-conjugation technique with a reversible amino-protective reagent. J. Pharmacol Exp. Ther. (1999) 290:368–372.
- TSUNODA S, ISHIKAWA T, WATANABE M et al.: Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino-protective reagent. Br. J. Haematology (2001) 112(1):181.
- KOZLOWSKI A, HARRIS MJ: Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Control. Release (2001) 72(1-3):217–224.
- MALIK F, BREW J, MAIDMENT SA, DELGADO C, FRANCIS GE: Peg-modified erythropoietin with improved efficacy. Exp. Hematology (2000) 28(7):106.
- ESPOSITO P, BARBERO L, CACCIA P et al.: PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv. Drug Del. Rev (2003) 55(10):1279–1291.
- LEE LS, CONOVER C, SHI C, WHITLOW M, FILPULA D: Prolonged circulating lives of single-chain Fy proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Biocorgug. Chem. (1999) 10:973–981.
- VERONESE FM: Peptide and protein PEGylation: a review of problems and solutions. Biomaterials (2001) 22:405–417.
- •A recent review of peptide and protein pegylation.
- GREENWALD RB: PEG drugs: an overview. J. Control. Release (2001) 74:159–171.
- MOREADITH RW, COLLEN D: Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction. Adv. Drug Del. Rev (2003) 55:1337–1345.
- GREGORIADIS G, JAIN S, PAPAIOANNOU I, LAING P: Improving the therapeutic efficacy of peptides and proteins: A role for polysialic acids. Int. J. Pharm. (2005) 300:125–130.
- •A recent report on the use of polysialic acids for delivery of peptides and proteins.
- GREGORIADIS G, MCCORMACK B, WANG Z, LIFELY R: Polysialic acids: potential in drug delivery. FEBS Lett. (1993) 315:271–276.
- FERNANDES A GREGORIADIS G: The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implications in its pharmacokinetics. Int. I Pharm. (2001) 217:215–224.
- JAIN S, HRECZUK-HIRST DH, MCCORMACK B et al: Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim. Biophys. Acta (2003) 1622:42–49.
- EPENETOS A, HRECZUK-HIRST DH, MCCORMACK B, GREGORIADIS G: Polysialylated proteins: a potential role in cancer therapy. Clin. Pharm. (2002) 21:2186.
- KIM J- BAGGIO L, BRIDON D et al: Development and characterization of a glucagon-like peptide 1-albumin conjugate-the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes (2003) 52:751–759.
- LAWRENCE B, DREYFUS JF, WEN S et al: CJC-1131, a long -acting GLP-1 derivative, exhibits an extended pharmacokinetic profile in healthy human volunteers. Annual ADA meeting. San Francisco, CA, USA (2003).
- HRECZUK-HIRST D, CO D, GERMAN L, DUNCAN R: Dextrins as potential carriers for drug targeting: tailored rates of dextrin degradation by introduction of pendant groups. Int. I Pharm. (2001) 230(1-2):57–66.
- DOMB AJ, LANGER R: Poly(anhydrides). 3. Poly(anhydrides) based on aliphatic-aromatic diacids. Macromolecules (1989) 22:3200–3204.
- HELLER J, BARR J, NG SY, ABDELLAUOI KS, GURNY R: Poly(ortho esters): synthesis, characterization, properties and uses. Adv. Drug Del. Rev. (2002) 54:1015–1039.
- KELLOMAKI M, PAASIMAA S, GRIJPMA DW, KOLPPO K, TORMALA P: LI vitro degradation of Polyactive® 1000PEOT7OPBT30 devices. Biomaterials (2002) 23:283–295.
- ZARIF L: Elongated supramolecular assemblies in drug delivery. J. Control. Release (2002) 81:7–23.
Websites
- http://www.guilfordpharm.com Guilford Pharmaceuticals company website.
- http://www.octoplus.n1 Octoplus company website.
- http://www.flamel.com Flamel Technologies company website.
- http://www.praecis.com Praecis Pharmaceuticals company website.
- http://www.neophrm.com NeoPharm company website.
- http://www.inexpharm.com Inex Pharmaceuticals company website.
- http://www.skyepharma.com SkyePharma company website.
- http://www.Mtinc.com QLT, Inc. company website
- http://www.macromed.com MacroMed, Inc. company website.
- http://www.appharma.com AP Pharma, Inc. company website.
- http://www.durect.com Durect company website.
- http://www.wyeth.com Wyeth company website.
- http://www.nektancom Nektar company website.
- http://www.lipoxen.com Lipoxen company website.
- http://www.conjuchem.com ConjuChem company website.